Latest News on MED

Financial News Based On Company


Advertisement
Advertisement

Medifast Inc (MDF.DU) Seasonal returns chart

https://uk.finance.yahoo.com/quote/MDF.DU/seasonality/
This article provides a seasonal returns chart for Medifast Inc (MDF.DU), showing its average monthly price return from 2020 to 2026. As of the latest quote, Medifast Inc (MDF.DU) was trading at 10.88 EUR, down 0.14 EUR or 1.27%. The chart helps visualize historical seasonality trends for the stock.

Form 4 Medifast Inc: Parsa Kiai (Director) For: 4 November By Investing.com

https://au.investing.com/news/stock-market-news/form-4-medifast-inc-parsa-kiai-director-for-4-november-93CH-4753168
This article reports on a Form 4 filing for Medifast Inc. involving Parsa Kiai, a director, for activity on November 4th. The brief announcement provides no specific details about the nature of the transaction.

Medifast director Parsa Kiai buys $8,609 in company stock

https://www.investing.com/news/insider-trading-news/medifast-director-parsa-kiai-buys-8609-in-company-stock-93CH-5009804
Medifast director Parsa Kiai indirectly acquired 661 shares of the company's common stock for $8,609 on November 4, 2026. This purchase, made at an average price of $13.0255 per share, increases Kiai's indirect holdings to 21,089 shares. The acquisition occurs as Medifast's stock trades near $12.81, with the company showing impressive gross profit margins despite profitability challenges, and having recently surpassed Q3 2026 financial expectations.

Form 4 Medifast Inc: Parsa Kiai (Director) For: 4 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-4-medifast-inc-parsa-kiai-director-for-4-november-93CH-4966399
This article reports a Form 4 filing for Medifast Inc., indicating that Parsa Kiai, a director, made a transaction on November 4th. The filing was published on November 7, 2026, by Investing.com. The article provides the basic detail of the insider transaction.

Medifast, Inc. (MDF.F) Analyst insights, Price targets and Recommendations - Yahoo Finance

https://sg.finance.yahoo.com/quote/MDF.F/analyst-insights/
This Yahoo Finance article provides analyst insights, price targets, and recommendations for Medifast, Inc. (MDF.F). It lists recent upgrades and downgrades from firms like Stephens & Co. and DA Davidson, detailing changes in ratings and the dates they occurred. The current stock price and market status are also displayed.
Advertisement

Weekly Recap: Q3 revenue decline and coach productivity growth

https://www.tradingview.com/news/tradingview:5a7e662b341e2:0-weekly-recap-q3-revenue-decline-and-coach-productivity-growth/
Medifast, Inc. (NYSE:MED) reported a 19.4% decline in Q3 revenue and a net loss of $17.51 million, despite a fourth consecutive quarter of increased revenue per active earning coach. The company's Project Catalyst, involving facility, technology, and workforce changes, aims to boost profitability, with Q4 revenue projected to be between $55 million and $75 million.

Form 4 Medifast Inc: Parsa Kiai (Director) For: 28 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-4-medifast-inc-parsa-kiai-director-for-28-october-93CH-4947155
This article reports on a Form 4 filing for Medifast Inc., indicating a transaction by Parsa Kiai, a Director, on October 28. The brief update was published by Investing.com.

Form 4 Medifast Inc: Parsa Kiai (Director) For: 28 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-medifast-inc-parsa-kiai-director-for-28-october-93CH-2772818
This article reports on a Form 4 filing for Medifast Inc., indicating that director Parsa Kiai engaged in a transaction on October 28. Form 4 filings are regulatory documents disclosing changes in the beneficial ownership of a company's securities by its officers, directors, or principal stockholders. The article provides the title of the filing and the date of the transaction.

Medifast, Inc. (MED) Seasonal returns chart

https://uk.finance.yahoo.com/quote/MED/seasonality/
The article provides a seasonal returns chart for Medifast, Inc. (MED), displaying the average monthly price return from 2016 to 2026. It includes current stock data such as the delayed NYSE quote, recent price movements, and after-hours trading information. The page also features navigation options for various financial data like news, statistics, historical data, and analysis related to Medifast.

Medifast, Inc. (MED) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/MED/seasonality/
This article from Yahoo Finance provides a seasonal returns chart for Medifast, Inc. (MED), displaying the average monthly price return between 2016 and 2026. The page also includes current stock information for Medifast, showing its price at market close and after hours.
Advertisement

MEDIFAST INC Estimates – NYSE:MED

https://www.tradingview.com/symbols/NYSE-MED/financials-estimates/
This article provides an overview of MEDIFAST INC (NYSE: MED) financials and analyst estimates available on TradingView. It highlights sections for exploring reported financial data, comparing actual results with estimates, and visualizing trends across income statements, balance sheets, cash flow statements, and valuation metrics. The content emphasizes that it is not investment advice and encourages users to conduct their own research.

Medifast Q3 Loss Narrower Than Expected as Coach Productivity Rises

https://es.tradingview.com/news/zacks:7065b0aec094b:0-medifast-q3-loss-narrower-than-expected-as-coach-productivity-rises/
Medifast (MED) reported a narrower-than-expected loss in Q3 2026, with an adjusted loss per share of 19 cents against an anticipated 40 cents. Despite a 19.4% year-over-year revenue decline to $72 million, the figure surpassed the Zacks Consensus Estimate of $68 million. The company saw a significant increase in average revenue per active earning coach, rising 54.1% year-over-year, marking the fourth consecutive quarter of productivity improvement, attributed to more efficient coach network structures.

Why Medifast (MED) stock is trading up today

https://markets.financialcontent.com/stocks/article/stockstory-2026-10-27-why-medifast-med-stock-is-trading-up-today
Shares of Medifast (MED) rose 6.2% after the company reported third-quarter results that surpassed Wall Street's sales expectations. CEO Nick Johnson stated that new brand initiatives are in the market, and the company is on track to deliver a profit in the fourth quarter. Medifast's shares have shown volatility but the market views this news as meaningful, though not fundamentally altering its perception of the business.

Medifast Q3 Loss Narrower Than Expected as Coach Productivity Rises

https://www.tradingview.com/news/zacks:7065b0aec094b:0-medifast-q3-loss-narrower-than-expected-as-coach-productivity-rises/
Medifast (MED) reported third-quarter 2026 results that surpassed Zacks Consensus Estimates for both top and bottom lines, despite a year-over-year revenue decline. The company posted a narrower-than-expected adjusted loss per share of 19 cents, and average revenue per active earning coach increased significantly. This improvement was attributed to a focus on developing more efficient coach network structures, even as the total number of active coaches decreased due to challenges in client acquisition, including the impact of GLP-1 weight-loss medications.

Form 144 MEDIFAST INC For: 27 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-medifast-inc-for-27-october-93CH-4905236
Investing.com reported on a Form 144 filing for Medifast Inc. (NYSE:MED) on October 27, 2026. The article indicates that this filing is a routine disclosure, often related to the intent to sell restricted or controlled securities. The content is brief and primarily serves as an alert for market participants interested in Medifast's insider or affiliate transactions.
Advertisement

Form 144 MEDIFAST INC For: 27 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-medifast-inc-for-27-october-93CH-2759485
The article reports the filing of Form 144 for Medifast Inc. on October 27, 2026. This form is typically used to notify the SEC of the intent to sell restricted or control securities. The brief announcement provides no further details beyond the company name and filing date.

What Medifast (MED) Said on Its Q3 Earnings Call

https://es.tradingview.com/news/marketbeat:668d7e11b094b:0-what-medifast-med-said-on-its-q3-earnings-call/
Medifast (MED) reported a 19.4% year-over-year revenue decline in Q3 2026, reaching $72 million, primarily due to a sharp reduction in active earning coaches. The company is responding with its "3.0" strategy, including the launch of its Trilivy metabolic health platform and revised coach compensation, while acknowledging the widespread impact of GLP-1 medications on the weight-loss market. Despite an operating loss and restructuring charges, Medifast aims for fourth-quarter profitability and anticipates further coach productivity gains.

Medifast, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:MED) 2026-10-26

https://seekingalpha.com/article/4957570-medifast-inc-2026-q3-results-earnings-call-presentation
Medifast, Inc. (NYSE:MED) published its Q3 2026 earnings call presentation, detailing its financial results. The company reported an EPS of -$0.19, beating estimates by $0.16, and revenue of $72.05M, a 19.42% year-over-year decrease, which still beat expectations by $748.00K. The article serves as a record of the presentation for investors.

Medifast Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62588579/medifast-q3-2026-earnings-call-transcript
Medifast reported Q3 2026 revenue of $72 million, aligning with guidance and stabilizing around $75 million for the fourth consecutive quarter. The company launched its TriLove brand and Metabolic Health Institute, shifting focus from weight loss to metabolic health, resulting in improved coach productivity despite fewer active coaches. Medifast maintains a strong financial position with $173 million in cash and no debt, targeting profitability in Q4 2026.

Medifast 3Q 2026: Revenue $72.05M, Net income ($17.51M), EPS ($1.57) — 10-Q Summary

https://www.tradingview.com/news/tradingview:936eb02c95fdc:0-medifast-3q-2026-revenue-72-05m-net-income-17-51m-eps-1-57-10-q-summary/
Medifast reported a significant decline in its third-quarter 2026 financial results, with revenue dropping by 19.4% to $72.05 million and a net loss of $17.51 million, a substantial increase from the prior year. The diluted loss per share was ($1.57), attributed to a decrease in active earning coaches. The company is actively implementing strategic shifts, including the launch of Trilivy and a new compensation plan, alongside Project Catalyst initiatives, to regain profitability and growth.
Advertisement

Medifast Q3 Revenue Falls 19.4% to $72 Million

https://grafa.com/en/news/united-states/medifast-q3-2026-revenue-declines-net-loss-guidance
Medifast reported a 19.4% year-over-year decline in third-quarter 2026 revenue, reaching $72 million, and a widened net loss of $17.5 million. The company faced a significant drop in active earning coaches, attributed to the rise of GLP-1 weight-loss medications, though average revenue per coach increased. Medifast provided fourth-quarter revenue guidance of $55 million to $75 million and expects full-year revenue between $280 million and $300 million.

Medifast (NYSE:MED) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations

https://markets.financialcontent.com/stocks/article/stockstory-2026-10-26-medifast-nysemed-exceeds-q3-2026-expectations-full-year-outlook-slightly-exceeds-expectations
Medifast (NYSE:MED) reported Q3 2026 results, exceeding Wall Street's revenue expectations despite a 19.4% year-on-year decline to $72.05 million. The company provided an optimistic outlook for Q4 2026 revenue and full-year EBITDA, surpassing analyst consensus estimates. However, GAAP EPS significantly missed estimates, and the stock edged lower by 1.2% immediately after the announcement.

Medifast: Q3 Earnings Snapshot

https://www.10tv.com/article/syndication/associatedpress/medifast-q3-earnings-snapshot/616-eb942ed6-5097-49a1-a53e-f3fbe94dea01
Medifast Inc. (MED) reported a third-quarter loss of $17.5 million, or $1.57 per share, with adjusted losses at 19 cents per share. The weight-loss company's revenue for the period was $72 million. Medifast provided a Q4 revenue outlook of $55 million to $75 million and full-year revenue guidance between $280 million and $300 million, expecting a full-year loss ranging from 70 cents to 45 cents per share.

Form 144 MEDIFAST INC For: 25 October By Investing.com

https://in.investing.com/news/stock-market-news/form-144-medifast-inc-for-25-october-93CH-5652936
The article reports on a Form 144 filing for Medifast Inc. (MED) on October 25. Form 144 filings typically indicate an insider's intent to sell restricted stock. The content provides the headline and mentions the associated stock ticker with a -2.47% change.

Form 144 MEDIFAST INC For: 25 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-medifast-inc-for-25-october-93CH-4901643
This article reports on the filing of Form 144 for MEDIFAST INC on October 25. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity or significant stock transactions. The article provides the title and date of the filing, along with the stock symbol MED, which showed a -2.47% change.
Advertisement

Medifast (MED) Q3 earnings report preview: what to look for

https://www.tradingview.com/news/stockstory:699b96af7094b:0-medifast-med-q3-earnings-report-preview-what-to-look-for/
Medifast (MED) is set to announce its Q3 earnings results before market hours this Monday. The market anticipates a 20.3% year-on-year revenue decline, an improvement from the previous year's 36.2% decrease. Analysts have largely maintained their estimates, and Medifast enters earnings with an average analyst price target of $12, slightly above its current share price of $11.85.

Medifast, Inc. Estimates – TRADEGATE:MDF

https://www.tradingview.com/symbols/TRADEGATE-MDF/financials-estimates/
This article provides access to financial actuals and analyst estimates for Medifast, Inc. (MDF) on the Tradegate Exchange, accessible via TradingView. Users can explore reported financial data and analyst estimates across various financial statements and visualize trends over time. The platform also offers comparisons between actual results and average, high, and low estimates.

Medifast, Inc. Estimates – MUN:MDF

https://www.tradingview.com/symbols/MUN-MDF/financials-estimates/
This page provides financial estimates for Medifast, Inc. (MDF) on the Munich Stock Exchange via TradingView. It allows users to explore reported financial data and analyst estimates across various statements and metrics, comparing actual results with average, high, and low estimates. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.

Medifast Q3 Earnings on the Horizon: Key Insights for Investors

https://www.tradingview.com/news/zacks:18f160274094b:0-medifast-q3-earnings-on-the-horizon-key-insights-for-investors/
Medifast (MED) is set to announce its Q3 fiscal 2026 results, with analysts predicting a significant decline in revenues and a wider loss per share due to challenges from GLP-1 medications and a shrinking coach base. Despite strategic initiatives like the Trilivy brand and cost-saving programs, the Zacks model does not conclusively predict an earnings beat. The article also highlights other companies like Sysco, Freshpet, and Hershey that show a favorable combination for an earnings beat.

Medifast stock: Zacks upgrades Medifast stock to Strong Buy

https://www.ad-hoc-news.de/boerse/news/nebenwerte/medifast-stock-zacks-upgrades-medifast-stock-to-strong-buy/70396447
Zacks Research has upgraded Medifast stock from Hold to Strong Buy on October 15, 2026, ahead of the company's third-quarter results announcement scheduled for October 26, 2026. The upgrade follows a weak second quarter where revenue fell by 27.60% year-over-year, but revenue per active earning coach increased by 41.00%. Medifast, listed on NYSE as MED, operates a coach-guided metabolic health system.
Advertisement

Medifast Inc (MDF.DU) Analyst insights, Price targets and Recommendations

https://uk.finance.yahoo.com/quote/MDF.DU/analyst-insights/
This article provides an overview of analyst ratings and recommendations for Medifast Inc (MDF.DU), focusing on upgrades, downgrades, and maintained ratings from firms like Stephens & Co. and DA Davidson. It lists several changes in analyst sentiment towards Medifast over recent years, including shifts between "Underperform," "Neutral," and "Equal-Weight" ratings. The current stock price and performance are also noted.

Zacks upgrades Medifast stock to Strong Buy ahead of October 26 results

https://www.ad-hoc-news.de/boerse/news/nebenwerte/zacks-upgrades-medifast-stock-to-strong-buy-ahead-of-october-26-results/70376513
Zacks Research upgraded Medifast (MED) stock from Hold to Strong Buy on October 13, 2026, ahead of the company's third-quarter earnings report scheduled for October 26, 2026. The health and wellness company, trading at EUR 10.67 on October 20, 2026, reported second-quarter revenue of USD 76.38 million and a net loss of USD 3.10 million. The upcoming earnings call will focus on customer growth and coach productivity as Medifast shifts towards its Trilivy metabolic health system.

Medifast (MED) Expected to Release Quarterly Earnings on Monday

https://www.marketbeat.com/instant-alerts/upcoming-medifast-med-expected-to-release-quarterly-earnings-on-monday-2026-10-19/
Medifast (NYSE:MED) is anticipated to release its Q3 2026 earnings after market close on Monday, October 26th, with analysts forecasting a loss of $0.35 per share and revenue of $71.30 million. The company's previous quarter surpassed expectations, reporting a smaller loss and higher revenue than predicted. Analyst consensus currently rates Medifast as "Hold" with a $12.00 price target, while insider trading activity has shown both share sales and purchases.

Medifast Q3 2026 Earnings Date and Estimates

https://www.marketbeat.com/earnings/reports/2026-10-26-medifast-inc-stock/
Medifast (NYSE: MED) is scheduled to report its Q3 2026 earnings on Monday, October 26, 2026, after market close, with a conference call at 8:30 AM ET. Analysts expect the company to post earnings of -$0.35 per share on revenue of $71.30 million, a decrease from the prior year's -$0.21 per share and $89.41 million in revenue. Medifast has a track record of beating EPS estimates, doing so in 6 of its last 8 quarters.

Medifast Inc (NYSE:MED) Sees Significant Decrease in Short Interest

https://www.marketbeat.com/instant-alerts/options-medifast-inc-nyse-med-sees-significant-decrease-in-short-interest-2026-10-15/
Medifast Inc (NYSE:MED) experienced a significant 43.4% decrease in short interest in September, bringing the total to 1.05 million shares, representing 9.8% of outstanding stock and a 7.3-day short-interest ratio. Insider transactions included Director Parsa Kiai buying 43,150 shares and Director Daniel Chard selling 9,544 shares. The company's shares are trading near the analyst consensus target of $12.00, and despite beating quarterly EPS and revenue estimates, Medifast remains unprofitable with an average "Hold" rating from analysts.
Advertisement

Medifast (NYSE:MED) Stock Bumped Up to Strong-Buy by Zacks Research

https://www.marketbeat.com/instant-alerts/analyst-medifast-nyse-med-stock-bumped-up-to-strong-buy-by-zacks-research-2026-10-15/
Zacks Research has upgraded Medifast (NYSE:MED) stock from a "hold" to a "strong-buy" rating. Despite this upgrade, overall analyst sentiment remains mixed, with a consensus "hold" rating and an average price target of $12.00 according to MarketBeat data. The company recently surpassed quarterly EPS and revenue expectations, but reported negative margins and return on equity, and saw mixed insider trading activity.

Can Medifast's Better Client Retention Support Revenue Stabilization?

https://www.tradingview.com/news/zacks:4a3c2dfd3094b:0-can-medifast-s-better-client-retention-support-revenue-stabilization/
Medifast is showing signs of business stabilization, with sequential revenue remaining steady despite a decline in its coach base. The company reported a 27.6% year-over-year revenue decrease in Q2 2026 but saw a 41% increase in average revenue per active earning coach, indicating improved productivity and client retention. Management projects Q3 2026 revenues between $60-$80 million, expecting continued coach count decline but further improvements in coach productivity.

Medifast presented Trilivy data and Medifast stock costs EUR 10.16

https://www.ad-hoc-news.de/boerse/news/nebenwerte/medifast-presented-trilivy-data-and-medifast-stock-costs-eur-10-16/70266150
Medifast stock traded at EUR 10.16 on October 8, 2026, slightly down from its previous close. The company recently presented new Trilivy metabolic-health data, highlighting 98.00% lean mass retention and a 14.00% reduction in visceral fat. Despite a decrease in active coaches, average revenue per coach increased, and the company anticipates progress toward profitability starting in Q4 2026.

Medifast stock faces a smaller coach base after Q2 revenue beat

https://www.ad-hoc-news.de/boerse/news/nebenwerte/medifast-stock-faces-a-smaller-coach-base-after-q2-revenue-beat/70249705
Medifast reported a Q2 revenue beat of $76.4 million, but its stock is under pressure due to a significant 48.7% year-over-year decrease in its active earning coach base. While coach productivity rose by 41%, the shrinking network continues to challenge revenue growth, with analysts holding a "Reduce" consensus and a price target slightly above the current market price. Management's guidance for Q3 and fiscal year 2026 indicates continued losses, emphasizing the need for improved recruitment and retention strategies.

Can Medifast's Better Client Retention Support Revenue Stabilization?

https://es.tradingview.com/news/zacks:4a3c2dfd3094b:0-can-medifast-s-better-client-retention-support-revenue-stabilization/
Medifast (MED) is showing signs of business stabilization despite a declining coach base, primarily due to higher coach productivity and improved client retention. While revenues were down year-over-year in Q2 2026, average revenue per active earning coach increased significantly, and the company's client referral program is exceeding expectations. Management anticipates continued revenue stabilization and improving coach productivity, though the active coach count is expected to decline in the short term.
Advertisement

Bank of America buys 87,118 Medifast shares for its portfolio

https://www.ad-hoc-news.de/boerse/news/nebenwerte/bank-of-america-buys-87-118-medifast-shares-for-its-portfolio/70240581
Bank of America purchased 87,118 shares of Medifast (MED) on October 3, 2026, giving it a 0.78% stake in the company. Medifast is currently reshaping its weight-management business around OPTAVIA and a broader metabolic-health strategy, with its stock trading at EUR 10.42 on October 6, 2026. The company reported a significant drop in Q2 2026 revenue and provided cautious guidance for the remainder of the year, expecting a return to profitability in Q4 2026.

Medifast stock gets a new Bank of America stake

https://www.ad-hoc-news.de/boerse/news/corporate-news/medifast-stock-gets-a-new-bank-of-america-stake/70237600
Bank of America has acquired 87,118 shares of Medifast stock, despite the company's weak Q2 2026 earnings, which saw revenue fall 27.6% year-over-year. Although revenue declined, the company reported a narrower EPS loss than expected. Analysts have given Medifast an average "Reduce" rating with a consensus price target slightly above its current share price.

Medifast director trust sells 19,089 shares. Medifast stock gains 1.67 percent

https://www.ad-hoc-news.de/boerse/news/nebenwerte/medifast-director-trust-sells-19-089-shares-medifast-stock-gains-1-67/70216630
A trust linked to Medifast director Daniel R. Chard sold 19,089 common shares of Medifast (MED) in late September 2026, executed under a Rule 10b5-1 trading plan. This insider sale occurred as Medifast's stock gained 1.67 percent, trading at EUR 10.34, despite the company reporting a 27.60 percent year-over-year decline in second-quarter 2026 revenue, which still exceeded analyst expectations.

Have Medifast Insiders Been Selling Stock?

https://www.moomoo.com/news/post/1000552143/have-medifast-insiders-been-selling-stock
This article examines recent insider trading activity at Medifast, focusing on whether insiders have been selling their stock. It implies a detailed look into transactions by company executives and directors to determine any trends or significant movements in their holdings.

Don't Ignore The Insider Selling In Medifast

https://simplywall.st/stocks/us/household/nyse-med/medifast/news/dont-ignore-the-insider-selling-in-medifast
A recent insider sale at Medifast (NYSE:MED) saw Non-Executive Chairman Daniel Chard divest US$226k worth of shares, representing 8.7% of his total holding. While this was the largest insider sale in the past year, the company also saw more insider buying than selling over the same period. Insiders collectively own 3.8% of Medifast stock, valued at US$4.5 million.
Advertisement

Q2 Earnings Roundup: Medifast (NYSE:MED) And The Rest Of The Personal Care Segment

https://www.tradingview.com/news/stockstory:7239671c7094b:0-q2-earnings-roundup-medifast-nyse-med-and-the-rest-of-the-personal-care-segment/
This article provides a Q2 earnings roundup for the personal care industry, highlighting the performance of several key companies. Medifast (MED) reported a strong quarter with revenues exceeding expectations and increased EPS guidance, while e.l.f. Beauty (ELF) stood out with significant revenue growth and analyst estimate beats. Conversely, Nature's Sunshine (NATR) experienced a disappointing quarter with misses on revenue, EBITDA, and EPS estimates.

Medifast (NYSE:MED) Stock: Insider Daniel Chard Sells 9,545 Shares

https://www.marketbeat.com/instant-alerts/insider-medifast-nyse-med-stock-insider-daniel-chard-sells-9545-shares-2026-09-30/
Medifast (NYSE:MED) Director Daniel Chard sold 9,545 shares of the company's stock for a total of $114,349.10, reducing his direct ownership by 6.38%. The transaction was part of a pre-arranged Rule 10b5-1 trading plan. Medifast shares recently traded at $11.53, with a market capitalization of $128.85 million, and analysts currently rate the stock as "Reduce" with an average price target of $12.00.

Medifast director Daniel Chard sells $226,288 in company shares

https://www.investing.com/news/insider-trading-news/medifast-director-daniel-chard-sells-226288-in-company-shares-93CH-4926141
Medifast director Daniel R. Chard sold a total of $226,288 worth of company common stock in two separate transactions in late September 2026. The sales involved 9,545 shares at a weighted-average price of $11.9788 and an additional 9,544 shares at $11.73. Despite the insider sales and a revenue decline, InvestingPro analysis suggests the stock is undervalued with significant upside potential.

Medifast (NYSE:MED) Stock: Insider Daniel Chard Sells 9,544 Shares

https://www.marketbeat.com/instant-alerts/insider-medifast-nyse-med-stock-insider-daniel-chard-sells-9544-shares-2026-09-30/
Medifast Director Daniel Chard sold 9,544 shares of the company's stock for $11.73 per share, totaling $111,951.12, reducing his holdings by 6.81%. The transaction was part of a pre-arranged Rule 10b5-1 trading plan. Despite recent analyst downgrades to "Reduce" and a negative P/E ratio, the company's latest quarterly earnings beat analyst expectations, and institutional investors hold a significant 95.51% stake.

A preset trading plan covers Medifast (MED) director Chard's trust sales of 9,545 and 9,544 shares.

https://www.stocktitan.net/sec-filings/MED/form-4-medifast-inc-insider-trading-activity-e9ef77a928e5.html
Medifast director Daniel R. Chard's irrevocable trust sold 9,545 common shares on September 28, 2026, at a weighted-average price of $11.9788, and 9,544 shares on September 29, 2026, at a weighted-average price of $11.7300. These transactions were executed under a Rule 10b5-1 plan, and Chard is the settlor and investment trustee of the selling trust. After these sales, Chard's holdings include 130,609.352 indirect shares through the trust, 17,678 indirect shares in a joint account, and 188,233 direct shares.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement